Related Experiment Videos
Immunologic defects in lung cancer patients.
The Journal of Thoracic and Cardiovascular Surgery
|February 1, 1976
Summary
Patients with lung cancer exhibit immune defects, particularly in antigen recognition. Early studies suggest Levamisole may help restore cellular immunity in these patients, potentially improving outcomes for lung cancer.
Area of Science:
- Oncology
- Immunology
- Cellular Biology
Background:
- Lung cancer patients often present with compromised immune function.
- Cellular immunity plays a critical role in anti-tumor responses.
- Assessing immune status can provide prognostic information in cancer patients.
Purpose of the Study:
- To evaluate the immune status of lung cancer patients using in vivo and in vitro methods.
- To investigate the association between immune defects and disease resectability.
- To explore the potential of Levamisole as an immunotherapeutic agent in lung cancer.
Main Methods:
- Delayed cutaneous hypersensitivity testing was performed on 93 lung cancer patients.
- In vitro lymphocyte function assays were conducted on 28 patients.
- Immune responses were assessed in 33 patients prior to surgical intervention.
Main Results:
- Immune response defects were significantly correlated with unresectable lung cancer.
- Both in vivo and in vitro findings indicated an antigen recognition defect in cellular immunity.
- Preliminary data suggested Levamisole's potential to enhance cellular immunity.
Conclusions:
- Defective cellular immunity, specifically antigen recognition, is a feature of lung cancer.
- Immune status evaluation may aid in predicting disease resectability.
- Levamisole shows promise as a modulator of immune function in lung cancer patients.